Scinai Immunotherapeutics (SCNI) Cash from Investing Activities (2018 - 2026)
Scinai Immunotherapeutics (SCNI) posted Cash from Investing Activities of $2.7 million for Q1 2026, up 91700.0% sequentially from -$3000.0 in Q2 2025, and up 30633.33% YoY from N/an in Q1 2025.
Scinai Immunotherapeutics (SCNI) Cash from Investing Activities (2018 - 2026) Analysis & Trends
Scinai Immunotherapeutics has reported Cash from Investing Activities for 9 years, with the latest figure at $2.7 million in Q1 2026.
- Quarterly Cash from Investing Activities rose 30633.33% year-over-year to $2.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.7 million (up 11891.3% YoY) and the FY2025 annual result came in at -$24000.0, down 100.0% from the prior year.
- Cash from Investing Activities grew to $2.7 million in Q1 2026 per SCNI's latest filing, from -$3000.0 in the prior quarter.
- Over five years, Cash from Investing Activities peaked at $2.7 million in Q1 2026 and troughed at -$1.0 million in Q4 2023.
- A 5-year average of $75466.7 and a median of -$10000.0 in 2024 frame the typical range for Cash from Investing Activities.
- The sharpest annual moves came in 2022 and 2026: Cash from Investing Activities tumbled 13125.0% in 2022, then soared 30633.33% in 2026.
- Over 5 years, Cash from Investing Activities stood at -$270000.0 in 2022, then plunged by 285.19% to -$1.0 million in 2023, then soared by 97.69% to -$24000.0 in 2024, then surged by 87.5% to -$3000.0 in 2025, then surged by 91700.0% to $2.7 million in 2026.
- According to Business Quant data, Cash from Investing Activities over the past three periods registered $2.7 million, -$3000.0, and -$9000.0 for Q1 2026, Q2 2025, and Q1 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 329.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -49.35 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -363.46 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -3.17 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 24.51 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -229.72 Mn |
| 10 | Scinai Immunotherapeutics | 11.72 Mn | -3.10 Bn | -1.12 Mn | 2.75 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.75 Mn |
| Mar 31, 2026 | 2.75 Mn |
| Jun 30, 2025 | -3,000.00 |
| Jun 30, 2025 | -3,000.00 |
| Mar 31, 2025 | -9,000.00 |
| Mar 31, 2025 | -9,000.00 |
| Dec 31, 2024 | -24,000.00 |
| Dec 31, 2024 | -24,000.00 |
| Sep 30, 2024 | 20,000.00 |
| Sep 30, 2024 | 20,000.00 |
| Jun 30, 2024 | -10,000.00 |
| Jun 30, 2024 | -10,000.00 |
| Mar 31, 2024 | 2,000.00 |
| Mar 31, 2024 | 2,000.00 |
| Dec 31, 2023 | -1.04 Mn |
| Dec 31, 2023 | -1.04 Mn |
| Sep 30, 2023 | 786,000.00 |
| Sep 30, 2023 | 786,000.00 |
| Jun 30, 2023 | -377,000.00 |
| Jun 30, 2023 | -377,000.00 |